findmyKOL
Clinical trialNCT07780565Not, yet, recruitingPhase 1Interventional

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

SponsorM.D. Anderson Cancer CenterEnrollment42Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical research study is to find the recommended dose of monzosertib in patients with relapsed/refractory AML and high-risk MDS. The safety and effects of monzosertib will also be studied.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ut Md Anderson Cancer Center

    Houston, Texas, United States

    Abhishek Maiti, MBBS

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IsavuconazoleMonzosertibPosaconazole →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jan 2027
Primary completion
30 Aug 2029
Completion
30 Aug 2031
Last update posted
21 Aug 2026
Registered enrollment
42
Registry id
NCT07780565
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.